Related Experiment Video
Updated: Oct 8, 2025
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With
Yasmine M Abdel Aziz1, Gehad Lotfy1, Mohamed M Said1
1Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
Abstract:
The tumor resistance to p53 activators posed a clinical challenge. Combination studies disclosed that concomitant administration of Bcl2 inhibitors can sensitize the tumor cells and induce apoptosis. In this study, we utilized a rapid synthetic route to synthesize two novel hybrid spirooxindole-based p53-MDM2 inhibitors endowed with Bcl2 signaling attenuation. The adducts mimic the thematic features of the chemically stable potent spiro [3H-indole-3,2'-pyrrolidin]-2(1H)-ones p53-MDM2 inhibitors, while installing a pyrrole ring via a carbonyl spacer inspired by the natural marine or synthetic products that efficiently inhibit Bcl2 family functions. A chemical insight into the two synthesized spirooxindoles including single crystal x-ray diffraction analysis unambiguously confirmed their structures. The synthesized spirooxindoles 2a and 2b were preliminarily tested for cytotoxic activities against normal cells, MDA-MB 231, HepG-2, and Caco-2 via MTT assay. 2b was superior to 5-fluorouracil. Mechanistically, 2b induced apoptosis-dependent anticancer effect (43%) higher than that of 5-fluorouracil (34.95%) in three studied cancer cell lines, activated p53 (47%), downregulated the Bcl2 gene (1.25-fold), and upregulated p21 (2-fold) in the treated cancer cells. Docking simulations declared the possible binding modes of the synthesized compounds within MDM2.
Insights
Novel spirooxindole compounds were synthesized to inhibit both p53-MDM2 and Bcl2 pathways, offering a new strategy against tumor resistance. Compound 2b demonstrated superior anticancer activity and apoptosis induction compared to 5-fluorouracil.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Cancer Research
Background:
- Tumor resistance to p53 activators presents a significant clinical hurdle.
- Combining p53 activators with Bcl2 inhibitors can sensitize tumor cells and promote apoptosis.
Purpose of the Study:
- To synthesize novel hybrid spirooxindole-based inhibitors targeting both p53-MDM2 and Bcl2 signaling pathways.
- To evaluate the anticancer potential and mechanism of action of these new compounds.
Main Methods:
- Rapid synthesis of hybrid spirooxindole compounds.
- Structural confirmation using single crystal X-ray diffraction.
- Cytotoxicity assessment via MTT assay and mechanistic studies including apoptosis, p53 activation, and gene expression analysis.
- Molecular docking simulations to predict binding modes.
Main Results:
- Two novel spirooxindole derivatives, 2a and 2b, were successfully synthesized and characterized.
- Compound 2b exhibited superior cytotoxic activity against cancer cell lines compared to 5-fluorouracil.
- Compound 2b induced significant apoptosis, activated p53, downregulated Bcl2, and upregulated p21 in cancer cells.
Conclusions:
- The synthesized spirooxindole hybrids effectively inhibit p53-MDM2 and Bcl2 signaling.
- Compound 2b shows promising anticancer efficacy through apoptosis induction, warranting further investigation for cancer therapy.
Related Concept Videos
02:23Abnormal Proliferation
01:31The Intrinsic Apoptotic Pathway